Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7337165 | 0.87 | KMT2A (0.41) | KMT2APOLBL3MBTL1ALDH1A1NPSR1 | |
| SCHEMBL6969986 | 0.87 | KMT2A (0.41) | KMT2APOLBL3MBTL1ALDH1A1NPSR1 | |
| SCHEMBL7132351 | 0.82 | L3MBTL1 (0.46) | KMT2AL3MBTL1ALDH1A1NPSR1HPGD | |
| SCHEMBL2606680 | 0.78 | KMT2A (0.52) | KMT2APOLBL3MBTL1DAOALDH1A1 | |
| SCHEMBL10402003 | 0.76 | KMT2A (0.50) | KMT2APOLBL3MBTL1DAOALDH1A1 | |
| SCHEMBL31560169 | 0.76 | KMT2A (0.50) | KMT2APOLBL3MBTL1DAOALDH1A1 | |
| SCHEMBL5421377 | 0.76 | KMT2A (0.50) | KMT2APOLBL3MBTL1DAOALDH1A1 | |
| SCHEMBL15880558 | 0.76 | LOX (0.48) | L3MBTL1ALDH1A1NPSR1LMNATDP1 | |
| SCHEMBL2120202 | 0.76 | KMT2A (0.50) | KMT2APOLBL3MBTL1DAOALDH1A1 | |
| SCHEMBL2012357 | 0.76 | KMT2A (0.50) | KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 222 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117050053-A | Novel thiophene antitumor compound and preparation method and application thereof | 北京中医药大学 | 2023-11-14 | — | — | CN | claimed |
| WO-2026104681-A1 | NEW SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2026-05-21 | — | — | WO | disclosed |
| US-12612384-B2 | Heterocyclic CYP4A inhibitor compounds and compositions thereof | MBD Co., Ltd. (KR) | 2026-04-28 | — | — | US | disclosed |
| US-12391647-B2 | Benzamide compound and preparation method, use, and pharmaceutical composition thereof | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2025-08-19 | — | — | US | disclosed |
| CN-119899170-A | Fluorine-containing thiophene compound, preparation method thereof and electrolyte | 江苏华盛锂电材料股份有限公司 | 2025-04-29 | — | — | CN | disclosed |
| US-20250115569-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | LARIO THERAPEUTICS LTD (GB) | 2025-04-10 | — | — | US | disclosed |
| EP-4436955-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | Lario Therapeutics Limited (GB) | 2024-10-02 | — | — | EP | disclosed |
| US-20240287032-A1 | NOVEL HETEROCYCLIC COMPOUND AND USE THEREOF | MBD Co., Ltd. (KR) | 2024-08-29 | — | — | US | disclosed |
| CN-118317950-A | Sulfonamide compounds for the treatment of neurological disorders | 拉里奥治疗有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-109942583-B | Aryl substituted aminotetrahydropyrans and uses thereof | 广东东阳光药业股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| WO-2007014011-A2 | N-(ARYLAMINO)-SULFONAMIDE INHIBITORS OF MEK | ARDEA BIOSCIENCES, INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| WO-2006034317-A2 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-03-30 | — | — | WO | disclosed |
| EP-1458715-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2005-12-07 | — | — | EP | disclosed |
| US-20050075346-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | US | disclosed |
| EP-1458715-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | disclosed |
| WO-2004043366-A2 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-05-27 | — | — | WO | disclosed |
| WO-2003051870-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | WO | disclosed |
| US-4237130-A | DIURETICS, HYPOTENSIVE AGENTS | MERCK & CO., INC. (US) | 1980-12-02 | — | — | US | disclosed |
| US-4115402-A | DIURETICS, SALURETICS, URICOSURIC AGENTS | MERCK & CO., INC. (US) | 1978-09-19 | — | — | US | disclosed |
| US-3991081-A | Fungicidal 2-(N-haloalkylthiosulfonamido)thiophenes | CHEVRON RESEARCH COMPANY (US) | 1976-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287032-A1 | NOVEL HETEROCYCLIC COMPOUND AND USE THEREOF | CYP4B1, CYP4A11, CYP3A4 | KMT2A 1455/4885POLB 4075/4885L3MBTL1 4482/4885 |
| US-12391647-B2 | Benzamide compound and preparation method, use, and pharmaceutical composition thereof | JAK2, STAT3, STAT5A | KMT2A 413/4885POLB 4345/4885L3MBTL1 4608/4885 |
| US-12612384-B2 | Heterocyclic CYP4A inhibitor compounds and compositions thereof | CYP4A11, CYP4B1, CYP4A22 | KMT2A 2591/4885POLB 1807/4885L3MBTL1 3606/4885 |
| US-20250115569-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | CACNA1A, CACNA1E, CACNA1S | KMT2A 919/4885POLB 3638/4885L3MBTL1 2457/4885 |
| US-20050075346-A1 | Novel compounds | CCL11, CCL2, CCL5 | KMT2A 4617/4885POLB 3343/4885L3MBTL1 4190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.